InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 0 (0%)+
Announcement
Release
26 Feb 2026 9:05AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited, through its subsidiary AdCella Pty Ltd, has convened a clinical advisory board to support the development of BZDS1901, a mesothelin-targeted CAR-T cell therapy for mesothelioma and other solid cancers. The advisory board is composed of leading physicians in the fields of oncology, immunology, and CAR-T cell therapies. Their role is to advise on clinical trial design, treatment standards, and emerging knowledge for BZDS1901. This strategic move is part of AdCella's efforts to leverage the integration of Asian T cell therapy development expertise with Australia's clinical and manufacturing capabilities to introduce innovative cellular immunotherapies to Western markets.
Key Points
  • AdAlta Limited convenes a clinical advisory board through its subsidiary AdCella Pty Ltd.
  • The advisory board will support the development of BZDS1901, a mesothelin-targeted CAR-T cell therapy.
  • The appointed board includes experts in oncology, immunology, and cell therapies.
  • Role includes advising on clinical trial design and emerging treatment standards.
  • Part of AdCella's strategy to integrate Asian and Australian expertise in cellular immunotherapy.
  • BZDS1901 aims to treat mesothelioma and other solid cancers.
  • AdCella's approach involves scalable, rapid ROI projects in T cell therapy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.